Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 393

1.

Myelodysplastic Syndromes.

Steensma DP.

Hematol Oncol Clin North Am. 2020 Apr;34(2):xv-xvi. doi: 10.1016/j.hoc.2019.12.001. Epub 2020 Jan 6. No abstract available.

PMID:
32089226
2.

Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.

Brunner AM, Steensma DP.

Hematol Oncol Clin North Am. 2020 Apr;34(2):379-391. doi: 10.1016/j.hoc.2019.10.003. Epub 2019 Dec 11. Review.

PMID:
32089217
3.

Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution.

Murrieta-Álvarez I, Steensma DP, Olivares-Gazca JC, Olivares-Gazca M, León-Peña A, Cantero-Fortiz Y, García-Navarrete YI, Cruz-Mora A, Ruiz-Argüelles A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Acta Haematol. 2020 Feb 11:1-7. doi: 10.1159/000505606. [Epub ahead of print]

PMID:
32045907
4.

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.

Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM.

Leuk Lymphoma. 2020 Feb 6:1-10. doi: 10.1080/10428194.2020.1723013. [Epub ahead of print]

PMID:
32026740
5.

Alexandre Yersin: Discoverer of the Plague Bacillus.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2020 Jan;95(1):e7-e8. doi: 10.1016/j.mayocp.2019.11.006. No abstract available.

PMID:
31902435
6.

Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.

Craig JW, Hasserjian RP, Kim AS, Aster JC, Pinkus GS, Hornick JL, Steensma DP, Coleman Lindsley R, DeAngelo DJ, Morgan EA.

Mod Pathol. 2020 Jan 2. doi: 10.1038/s41379-019-0447-x. [Epub ahead of print]

PMID:
31896808
7.

X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation.

Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP.

J Clin Invest. 2020 Jan 2;130(1):552. doi: 10.1172/JCI132538. No abstract available.

8.

Clonal hematopoiesis as a model for premalignant changes during aging.

Steensma DP, Ebert BL.

Exp Hematol. 2019 Dec 12. pii: S0301-472X(19)31133-6. doi: 10.1016/j.exphem.2019.12.001. [Epub ahead of print]

PMID:
31838005
9.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT.

Lancet Haematol. 2020 Feb;7(2):e122-e133. doi: 10.1016/S2352-3026(19)30203-0. Epub 2019 Dec 11.

PMID:
31837959
10.

Does early diagnosis and treatment of myelodysplastic syndromes make a difference?

Steensma DP.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101099. doi: 10.1016/j.beha.2019.101099. Epub 2019 Oct 18. Review.

PMID:
31779983
11.

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS.

Sperling AS, Leventhal M, Gibson CJ, Ebert BL, Steensma DP.

Leuk Lymphoma. 2020 Mar;61(3):728-731. doi: 10.1080/10428194.2019.1689394. Epub 2019 Nov 12. No abstract available.

PMID:
31714164
12.

The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).

Steensma DP.

Curr Hematol Malig Rep. 2019 Dec;14(6):536-542. doi: 10.1007/s11899-019-00547-3. Review.

PMID:
31696381
13.

Luke Fildes and The Doctor.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2019 Nov;94(11):e131-e132. doi: 10.1016/j.mayocp.2019.09.016. No abstract available.

PMID:
31685164
14.

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP.

JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00119. Epub 2019 Sep 20.

15.

Baron Aarnoud van Heemstra, Humanitarian Governor of Suriname and Grandfather of Audrey Hepburn.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2019 Sep;94(9):e111-e112. doi: 10.1016/j.mayocp.2019.07.015. No abstract available.

PMID:
31486391
16.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
17.

Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission.

Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A.

Cancer. 2019 Nov 1;125(21):3845-3852. doi: 10.1002/cncr.32397. Epub 2019 Jul 12.

PMID:
31299106
18.

Albert Schweitzer: Humanitarian With a "Reverence for Life".

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2019 Jul;94(7):e91-e92. doi: 10.1016/j.mayocp.2019.05.009. No abstract available.

PMID:
31272587
19.

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK.

Blood Adv. 2019 May 14;3(9):1540-1545. doi: 10.1182/bloodadvances.2019000090.

20.

Andreas Vesalius and De Fabrica.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2019 May;94(5):e67-e68. doi: 10.1016/j.mayocp.2019.03.018. No abstract available.

PMID:
31054619
21.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

PMID:
30926081
22.

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.

El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA.

Leukemia. 2019 Oct;33(10):2393-2402. doi: 10.1038/s41375-019-0449-1. Epub 2019 Mar 28.

PMID:
30923318
23.

John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2019 Mar;94(3):e45-e46. doi: 10.1016/j.mayocp.2019.01.023. No abstract available.

PMID:
30832803
24.

Rethinking clinical trial endpoints in myelodysplastic syndromes.

Sekeres MA, Steensma DP.

Leukemia. 2019 Mar;33(3):570-575. doi: 10.1038/s41375-018-0367-7. Epub 2019 Jan 30. Review.

PMID:
30700839
25.

Georges de Bellio (1826-1894): Doctor, Friend, and Patron of the Impressionist Painters.

Dumitrascu DL, Kyle RA, Steensma DP.

Mayo Clin Proc. 2019 Jan;94(1):e7. doi: 10.1016/j.mayocp.2018.11.009. No abstract available.

PMID:
30611460
26.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Steensma DP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):264-269. doi: 10.1182/asheducation-2018.1.264. Review.

27.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Steensma DP.

Blood Adv. 2018 Nov 27;2(22):3404-3410. doi: 10.1182/bloodadvances.2018020222. Review.

28.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S.

Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7.

PMID:
30404811
29.

Herman Boerhaave - Master Clinician and Humanist.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 Nov;93(11):e119-e120. doi: 10.1016/j.mayocp.2018.09.014. No abstract available.

PMID:
30392557
30.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA.

Cancer. 2018 Dec 15;124(24):4601-4609. doi: 10.1002/cncr.31769. Epub 2018 Oct 5.

31.

An RNA bestiary in splicing-mutant MDS.

Steensma DP.

Blood. 2018 Sep 20;132(12):1217-1219. doi: 10.1182/blood-2018-07-859942. No abstract available.

PMID:
30237252
32.

Werner Forssmann: A Pioneer of Interventional Cardiology and Auto-Experimentation.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2018 Sep;93(9):e97-e98. doi: 10.1016/j.mayocp.2017.08.026. No abstract available.

PMID:
30193685
33.

How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.

Steensma DP.

Blood. 2018 Oct 18;132(16):1657-1663. doi: 10.1182/blood-2018-06-860882. Epub 2018 Sep 5. Review. Erratum in: Blood. 2018 Nov 29;132(22):2419.

PMID:
30185432
34.

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia.

El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, Hobbs G, Foster J, Brunner A, Amrein P, Stone RM, Temel JS.

Oncologist. 2019 Feb;24(2):247-254. doi: 10.1634/theoncologist.2018-0317. Epub 2018 Aug 23.

35.

Clinical Implications of Clonal Hematopoiesis.

Steensma DP.

Mayo Clin Proc. 2018 Aug;93(8):1122-1130. doi: 10.1016/j.mayocp.2018.04.002. Epub 2018 Jul 4. Review.

PMID:
30078412
36.

Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes.

Zhang Q, Steensma DP, Yang J, Dong T, Wu MX.

Leukemia. 2019 Jan;33(1):217-229. doi: 10.1038/s41375-018-0204-z. Epub 2018 Jul 26.

PMID:
30050123
37.

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.

Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS.

BMJ Open. 2018 Jul 23;8(7):e019955. doi: 10.1136/bmjopen-2017-019955.

38.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

39.

Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes.

Brunner AM, Weng S, Cronin A, Fathi AT, Habib AR, Stone R, Graubert T, Steensma DP, Abel GA.

Am J Hematol. 2018 Sep;93(9):1119-1126. doi: 10.1002/ajh.25166. Epub 2018 Aug 28.

40.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.

Riley LG, Heeney MM, Rudinger-Thirion J, Frugier M, Campagna DR, Zhou R, Hale GA, Hilliard LM, Kaplan JA, Kwiatkowski JL, Sieff CA, Steensma DP, Rennings AJ, Simons A, Schaap N, Roodenburg RJ, Kleefstra T, Arenillas L, Fita-Torró J, Ahmed R, Abboud M, Bechara E, Farah R, Tamminga RYJ, Bottomley SS, Sanchez M, Huls G, Swinkels DW, Christodoulou J, Fleming MD.

Haematologica. 2018 Dec;103(12):2008-2015. doi: 10.3324/haematol.2017.182659. Epub 2018 Jul 19.

41.

Henry David Thoreau's Final Journey: Minnesota.

Steensma DP, Roede CA, Kyle RA.

Mayo Clin Proc. 2018 Jul;93(7):e75-e76. doi: 10.1016/j.mayocp.2017.07.021. No abstract available.

PMID:
29976384
42.

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):528-532. doi: 10.1016/j.clml.2018.05.016. Epub 2018 May 26.

PMID:
29937400
43.

Myelodysplastic syndromes current treatment algorithm 2018.

Steensma DP.

Blood Cancer J. 2018 May 24;8(5):47. doi: 10.1038/s41408-018-0085-4. Review.

44.

Cancer research in the United States: A critical review of current status and proposal for alternative models.

Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J.

Cancer. 2018 Jul 15;124(14):2881-2889. doi: 10.1002/cncr.31522. Epub 2018 May 14. Review. No abstract available.

45.

Fertility preservation in women with marrow failure syndromes prior to allogeneic stem cell transplantation.

Mehm AR, Steensma DP, Srouji SS, Ginsburg ES, Brady PC.

Am J Hematol. 2018 May 13. doi: 10.1002/ajh.25130. [Epub ahead of print] No abstract available.

46.
47.

Jöns Jacob Berzelius - A Father of Chemistry.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 May;93(5):e53-e54. doi: 10.1016/j.mayocp.2017.07.020. No abstract available.

PMID:
29728209
48.

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP 3rd, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK.

Blood. 2018 Jun 21;131(25):2816-2825. doi: 10.1182/blood-2018-01-828467. Epub 2018 May 3.

49.

New Insights from Studies of Clonal Hematopoiesis.

Gibson CJ, Steensma DP.

Clin Cancer Res. 2018 Oct 1;24(19):4633-4642. doi: 10.1158/1078-0432.CCR-17-3044. Epub 2018 Apr 27. Review.

50.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Nov;59(11):2723-2726. doi: 10.1080/10428194.2018.1452219. Epub 2018 Apr 18. No abstract available.

PMID:
29667455

Supplemental Content

Loading ...
Support Center